Barely Significant
← all excerpts

SAT-260 Comparative Efficacy of Olpasiran and Zerlasiran in Reducing Lipoprotein(a) Levels: A Network Meta-Analysis of Clinical Trials

J Endocr Soc · 2025 · PMC12546071

Europe PMC
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

borderline significantp = 0.05actually significant
For LDL cholesterol, Olpasiran showed a modest reduction (MD: -10.22 mg/dL, 95% CI: [-33.50; 13.06], p = 0.39), while Zerlasiran achieved a more substantial but borderline significant effect (MD: -23.94 mg/dL, 95% CI: [-48.11; -0.22], p = 0.05).

also in 6,181 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.